Sign In
Last checked at 
13 Nov 2025 07:00
REACH - Non-regulatory announcement*
13 November 2025
Fusion Antibodies plc
("Fusion" or the "Company")
OptiMAL Library video
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, has prepared a short video of Dr Richard Buick, CSO, explaining some of the features, science and technology behind the Company's Opti-library of antibody sequences.
The Opti-library design and method is protected by US patent no. 17/287,441. It has been combined with Fusion's mammalian display platform to create the OptiMAL® library, and it intended to be used to discover novel human antibodies against any target. OptiMAL® is due for commercial launch in December 2025.
The video can be viewed on the Investor Hub section of Fusion's website at, https://investorhub.fusionantibodies.com/s/7ea305.
This video is the latest in a series of videos providing shareholders and investors with more information on the Company's technological platforms and service offerings. These videos can be found here https://investorhub.fusionantibodies.com/s/1b6535.
Enquiries:
Investor questions on this announcement | ||
We encourage all investors to share questions on this announcement via our investor hub | Investor hub | |
| ||
Fusion Antibodies plc | www.fusionantibodies.com | |
Adrian Kinkaid, Chief Executive Officer Stephen Smyth, Chief Financial Officer | Via Walbrook PR | |
| ||
Allenby Capital Limited | Tel: +44 (0) 20 3328 5656 | |
James Reeve/Vivek Bhardwaj (Corporate Finance) Tony Quirke/Joscelin Pinnington (Sales and Corporate Broking) | ||
| ||
Shard Capital Partners LLP | ||
Damon Heath (Joint Broker) | Tel: +44 (0) 207 186 9952 | |
| ||
Walbrook PR | Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com | |
Anna Dunphy | Mob: +44 (0)7876 741 001 | |
About Fusion Antibodies plc
Fusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.
The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.
The Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.
Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.
*About Reach announcements
This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.
Follow the stocks
